Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days

Investigational New Drugs

Volumn 14, Issue 4, 1996, Pages 379-386

  Rassmann I ^a   Schrodel H ^a   Schilling, T ^a   Zucchetti, M ^b   Kaeser Frohlich A ^c   Rastetter, J ^a   Hanauske, A R ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c ASTA MEDICA AG   (Germany)

Author keywords

Dimethylaminoetoposide; NK611; Pharmacokinetics; Phase I

Indexed keywords

2'' DEOXY 2'' (DIMETHYLAMINO)ETOPOSIDE; PODOPHYLLOTOXIN DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRY EYE; DYSPHAGIA; FATIGUE; FEMALE; GRANULOCYTOPENIA; HEARTBURN; HOARSENESS; HUMAN; INFECTION; LEUKOPENIA; MALAISE; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PODOPHYLLOTOXIN;

EID: 0030469423     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Machida M, Tanaka S, Nakamori K: Simultaneous determination of NK611, a novel water-soluble derivative of etoposide, and its metabolite (DeNK611) in dogs plasma by column-switching high performance chromatography. Biomedic Chromatograph 7:82-85, 1993
2. Asta Medica GmbH. Investigator's drug brochure: NK611. Asta Medica GmbH 1993, p. 35
3. Ekimoto H, Okamoto K, Kusuma K, Mashiba H, Takeuchi T: Treatment schedule dependency of antitumor effects of NK611, a novel water-soluble analog of etoposide, on human xenografts. Proc Amer Assoc Cancer Res 33:436, 1992
4. Pagani O, Zucchetti M, Sessa C, De Jong J, D'Incalci M, De Fusco M, Kaeser-Fröhlich A, Hanauske A-R, Cavalli F: Phase I clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. In press 1996
5. Hainsworth JD, Greco FA: Etoposide: twenty years later. Ann Oncol 6:325-341, 1995
6. Ekimoto H, Okamoto K, Maruyma S, Mashiba S, Nakamori K, Takeuchi T: Preclinical characterization of NK611, a nov-el water-soluble etoposide analog. Ann Oncol 3(suppl. 1):98, 1992
7. Hanauske A-R, Wüster KC, Lehmer A, Rotter M, Schneider P, Kaeser-Fröhlich A, Rastetter J, Depenbrock H: Activity of NK611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumors in vitro. Eur J Cancer 31A:1677-1681, 1995
8. Zucchetti M, De Fusco M, Sessa C, Fröhlich A, Reichert S, D'Incalci M: High-performance liquid chromatographic assay for determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma. J Chromatogr 654B:97-102, 1994
9. De Fusco M, D'Incalci M, Gentili B, Reichert S, Zucchetti M: High performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine in cancer patients. J Chromatogr B 664:409-412, 1995
10. Sacchi-Landriani G, Guardabasso V, Rocchetti M: NI-Fit: a microcomputer program for non-linear fitting. Comput Programs Biomed 16:35-38, 1983
11. Greco FA: Chronic etoposide administration: overview of clinical experience. Cane Treat Rev 19(Suppl C):35-45, 1993
12. Schilling T, Mross K, Berdel WE, Manegold C, Fiebig HH, Rastetter J, Hanauske A-R: Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611. Ann Oncol 5(Suppl 5):193, 1994